



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,354	12/01/2003	Izumi Kawada	Q78626	8084

23373 7590 07/05/2005

SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON, DC 20037

EXAMINER

TATE, CHRISTOPHER ROBIN

ART UNIT PAPER NUMBER

1655

DATE MAILED: 07/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/724,354

Applicant(s)

KAWADA ET AL.

Examiner

Christopher R. Tate

Art Unit

1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>1203 & 0504</u> . | 6) <input type="checkbox"/> Other: ____. |

5-2-2

Art Unit: 1654

DETAILED ACTION

Claims 1-9 are presented for examination on the merits.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 4, and 5 are rejected under 35 U.S.C. 102(b) as being anticipated by Iwami et al (JP 2002-053857: full English translation by computer enclosed).

A skin cosmetic comprising a *Carya* seed (e.g., pecan) extract or *Carya* seed husk extract in an amount from 0.00005 to 2% by wt., and an additional agent (such as vitamin E) is claimed.

Iwami et al. teach skin cosmetic compositions (e.g., milky lotion, creams, lip stick) comprising *Carya* seed (e.g., pecan) extract or *Carya* seed husk extract (as an antioxidant color fading inhibitor therein) within the % wt. range instantly claimed, and an additional agent such as vitamin E (see entire English translation including Claims, Detailed Description, Examples).

Therefore, the reference is deemed to anticipate the instant claims above.

Claim 1 rejected under 35 U.S.C. 102(b) as being anticipated by Kawada (JP 2000-072686: full English translation by computer enclosed).

Art Unit: 1654

Kawada teaches skin cosmetic compositions (e.g., milky lotion, creams, gels) comprising *Carya* seed (e.g., pecan) extract or *Carya* seed husk extract (as an antioxidant therein) in an amount of .02-2% by wt., and an additional agent such as an emollient, emulsifier, and/or perfume (see entire English translation including Claims, Detailed Description, Examples). In addition, please note that Applicants readily admit that the instantly disclosed method of making the claimed extract preparation is an illustrative example of the extract method of JP 2000-72686 (see, e.g., page 8, lines 10-11, of the instant specification). Accordingly, the *Carya* extract employed in the skin cosmetic compositions disclosed by Kawada is admittedly (and, thus, inherently) the same as the *Carya* extract used within the instantly claimed composition (please note that this also appears to be true for the Iwami et al. reference discussed above since Kawada is also a named inventor therein and the same extraction steps are apparently employed in both the Kawada and Iwami et al. references).

Therefore, the reference is deemed to anticipate the instant claims above.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Iwami et al (JP 2002-053857: full English translation by computer enclosed) in view of Tominaga (US 5,747,049) and Trinh (US 5,540,853).

Art Unit: 1654

Iwami et al. is relied upon for the reasons discussed above. In addition, Iwami et al. teach incorporation of pecan extract within skin cosmetic compositions (e.g., milky lotion, creams, lipstick) that contain carotinoid-coloring matter (such as beta-carotene) therein so as to beneficially inhibit color fading (see entire document including paragraph [0024]).

Tominaga beneficially teaches skin cosmetic compositions (including cleansing compositions) which comprise or may comprise a pigment such as a natural dye including beta-carotene; an anti-inflammatory agent such as glycyrrhizic acid (or derivative) and allantoin; a fatty acid soap (including from 8 to 20 carbons) and an amphoteric surface active agent (such as an alkyl betaine or an amido betaine) and/or an alkanolamide nonionic surface active agent, as well as one or more therapeutic plant extracts therein for their known advantageous effects on the skin (see entire document including col 1, lines 15-60; col 6, line 40 - col 8, line 50; col 9, line 26; col 11, lines 15-17). Trinh also beneficially teaches skin cosmetic compositions (including cleansing compositions) which comprise or may comprise a colorant as well as an agent (preservative) to prevent color degradation; an anti-inflammatory agent such as glycyrrhizic acid (or derivative) and allantoin; a fatty acid soap (including from 8 to 20 carbons) and an amphoteric surface active agent (such as an alkyl betaine or an amido betaine) and/or an alkanolamide nonionic surface active agent therein for their known advantageous effects on the skin (see entire document including Abstract; col 7, line 3 - col 11, line 63; col 14, lines 53-56; col 29, lines 8-16; col 30, lines 4-11; col 44, line 43 - col 45, line 21).

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to add the pecan extract taught by Iwami et al. to a skin cosmetic composition that comprises a natural dye/colorant - e.g., beta-carotene (such as disclosed by

Art Unit: 1654

Tominaga and/or Trinh) so as to beneficially inhibit color fading of the natural dye/colorant therein based upon the beneficial teachings provided by Iwami et al., as discussed above. The adjustment of particular conventional working conditions (e.g., incorporating one or more commonly employed skin therapeutic agents - e.g., an anti-inflammatory agent, a fatty acid soap, an amphoteric surface active agent and/or an alkanolamide nonionic surface active agent - such as those beneficially taught by Tominaga and Trinh) within such a skin cosmetic/cleansing composition is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Trinh et al (US 5,540,853) and Tominaga (US 5,747,049) in view of Kawada (JP 2000-072686: full English translation by computer enclosed).

Kawada is relied upon for the reasons discussed above. In addition, Kawada teaches that the pecan extract beneficially acts as an antioxidant (active oxygen scavenger) within such skin cosmetic compositions (see entire document including Abstract)

Trinh beneficially teaches skin cosmetic compositions (including cleansing compositions) which comprise or may comprise an antioxidant; vitamins such as vitamin E, A, and/or C; an anti-inflammatory agent such as glycyrrhizic acid (or derivative) and allantoin; a fatty acid soap (including from 8 to 20 carbons) and an amphoteric surface active agent (such as an alkyl betaine or an amido betaine) and/or an alkanolamide nonionic surface active agent therein for their known advantageous effects on the skin (see entire document including Abstract; col 7, line 3 - col 11, line 63; col 14, lines 53-56; col 29, lines 8-16; col 30, lines 4-11; col 44, line 43 - col 45, line 21). Tominaga also beneficially teaches skin cosmetic compositions (including cleansing compositions) which comprise or may comprise an agent that acts as an antioxidant (e.g., vitamin E); other vitamins including vitamins A and/or C; an anti-inflammatory agent such as glycyrrhizic acid (or derivative) and allantoin; a fatty acid soap (including from 8 to 20 carbons) and an amphoteric surface active agent (such as an alkyl betaine or an amido betaine) and/or an alkanolamide nonionic surface active agent, as well as one or more therapeutic plant extracts therein for their known advantageous effects on the skin (see entire document including col 1, lines 15-60; col 6, line 40 - col 8, line 50; col 9, line 26; col 11, lines 15-17).

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to include the pecan extract taught taught by Kawada to a skin cosmetic composition (such as disclosed by Trinh and/or Tominaga) so as to beneficially act as an effective antioxidant therein based upon the beneficial teachings provided by Kawada, as discussed above. The adjustment of particular conventional working conditions (e.g., incorporating one or more commonly employed skin therapeutic agents - e.g., an anti-inflammatory agent, one or more vitamins, a fatty acid soap, an amphoteric surface active agent

Art Unit: 1654

and/or an alkanolamide nonionic surface active agent - such as those beneficially taught by Trinh and Tominaga) within such a skin cosmetic/cleansing composition is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

No claim is allowed.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher R. Tate whose telephone number is (571) 272-0970. The examiner can normally be reached on Mon-Thur, 6:30-4:00.

Art Unit: 1654

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, appearing to read 'Christopher R. Tate', with a stylized, looping flourish.

Christopher R. Tate
Primary Examiner
Art Unit 1654